OncoMatch/Clinical Trials/NCT04965454
Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma
Is NCT04965454 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Fluorine-18 fluorocholine for hepatocellular carcinoma non-resectable.
Treatment: Fluorine-18 fluorocholine — This prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this diagnostic trial is to assess the accuracy of pre-treatment fluorine-18 (18F-) fluorocholine (FCH) PET/CT for predicting a lack of objective response (LOR) after 16 weeks of ICI therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Lab requirements
Blood counts
Deemed eligible for treatment with an immune checkpoint inhibitor agent based on ... hematologic function
Kidney function
Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula
Liver function
ALT and AST ≤7x upper limit of normal; Total bilirubin ≤4 mg/dL; Albumin ≥2.8 g/dL; Child-Pugh score of 9 or less
Child-Pugh score of 9 or less; Creatinine clearance ≥ 40 mL/min, measured or calculated using the Cockcroft-Gault formula; ALT and AST ≤7x upper limit of normal; Total bilirubin ≤4 mg/dL; Albumin ≥2.8 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Queen's Medical Center · Honolulu, Hawaii
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify